cck-b receptor

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).

Itriglumide (CR-2945) 是一种胆囊收缩素 （CCK）-2 受体拮抗剂，具有抗分泌和抗溃疡作用。

PD 135158 is a CCK2 receptor antagonist.

PD-149164 is an agonist of the CCK-A receptor.

TP-680 is a antagonist of cholecystokininA receptor.

Proglumide (Binoside) 是一种非肽的、口服具有活性的胆囊收缩素(CCK)-A B 受体拮抗剂。它能够选择性阻断 CCK 在中枢神经系统中的作用。它能够抑制胃分泌，具有保护胃十二指肠粘膜的能力，并表现出抗癫痫和抗氧化活性。

Sincalide (CCK-8) 是一种速效的胆囊收缩素的氨基酸多肽激素类似物，可在胆囊造影术中静脉使用。它的肝胆生理作用是增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。它是一种通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病的药物。

YM022 is a highly effective and selective gastrin cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.

CCK2 (CCK-B) receptor antagonist

L-365260 是一种可口服且具有选择性和高效性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂。L-365260 抑制 CCK-8S 诱导的 [Ca2+]i 增加，可阻断应激引起的内脏超敏反应，可阻断 CCK-4 的抗探索作用，可用于研究神经系统Ojibwa和内分泌疾病。

CI-1015 is a CCK-B receptor antagonist with oral activity.

L-736380 is a CCK-B receptor antagonist. L-736,380 dose-dependently inhibited gastric acid secretion in anesthetized rats (ID(50), 0.064 mg kg) and ex vivo binding of [(125)I]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg kg).

L-740093 is a specific antagonist of CCK-B receptor.

Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o

L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂，Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。

[Leu15]-Gastrin I human acetate(39024-57-2 Free base) 是一种肽，通过 G 蛋白偶联受体，即胆囊收缩素 (CCK) 或 CCK-B 受体 (CCK-BR) 发挥作用。